Ewha Womans University

Curocell's CAR-T Therapy Rimqarto (Anbal-cel) Nears South Korean Market Launch

5 months ago

• Curocell's Rimqarto (Anbal-cel), a CAR-T therapy for relapsed or refractory large B-cell lymphoma (LBCL), is nearing market launch in South Korea. • Rimqarto demonstrated a 67.1% complete response rate in Phase 2 clinical trials, showcasing its efficacy and safety profile. • The therapy has been granted orphan drug designation and is under expedited review for approval and reimbursement in South Korea. • Curocell is also exploring global expansion opportunities for Rimqarto, including potential partnerships in South America, the Middle East, and Southeast Asia.